Beyond Air (NASDAQ:XAIR) Posts Earnings Results, Beats Expectations By $0.12 EPS

Beyond Air (NASDAQ:XAIRGet Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.12, Yahoo Finance reports. Beyond Air had a negative net margin of 5,197.76% and a negative return on equity of 203.12%. The business had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.72 million. During the same quarter last year, the firm earned ($0.45) EPS.

Beyond Air Price Performance

XAIR stock traded down $0.02 during trading on Wednesday, hitting $0.48. The company had a trading volume of 530,248 shares, compared to its average volume of 528,224. Beyond Air has a fifty-two week low of $0.48 and a fifty-two week high of $3.90. The company has a current ratio of 3.80, a quick ratio of 3.61 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $22.03 million, a price-to-earnings ratio of -0.28 and a beta of -0.10. The business has a 50 day moving average of $0.83 and a 200 day moving average of $1.29.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Truist Financial decreased their price objective on shares of Beyond Air from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. BTIG Research cut shares of Beyond Air from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 25th. Finally, Piper Sandler dropped their target price on shares of Beyond Air from $3.50 to $1.00 and set an “overweight” rating for the company in a report on Wednesday.

Check Out Our Latest Stock Report on XAIR

About Beyond Air

(Get Free Report)

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.

Featured Articles

Earnings History for Beyond Air (NASDAQ:XAIR)

Receive News & Ratings for Beyond Air Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyond Air and related companies with MarketBeat.com's FREE daily email newsletter.